RoglianiP, LauroD, Di DanieleN, ChettaA, CalzettaL: Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?. Expert Rev Respir Med. 2020; 15:561–568.
2.
IzquierdoJL, AlmonacidC, GonzalezY, Del Rio-BermudezC, AncocheaJ, CardenasR, LumbrerasS, and SorianoJB: The impact of COVID-19 on patients with asthma. Eur Respir J. 2021; 57:2003142.
3.
SchultzeA, WalkerAJ, MacKennaB, MortonCE, BhaskaranK, BrownJP, RentschCT, WilliamsonE, DrysdaleH, CrokerR, BaconS, HulmeW, BatesC, CurtisHJ, MehrkarA, EvansD, InglesbyP, CockburnJ, McDonaldHI, TomlisonL, MathurR, WingK, WongAYS, ForbesH, ParryJ, HesterF, HarperS, EvansSJW, QuintJ, SmeethL, DouglasIJ, Goldacre B (Open SAFELY Collaborative). Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020; 8:1106–1120.
4.
ChoiYJ, ParkJY, LeeHS, SuhJ, SongJY, ByunMK, ChoJH, KimHJ, LeeJH, ParkJW, ParkHJ: Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021.
5.
BloomCI, DrakeTM, DochertyAB, LipworthBJ, JohnstonSL, Nguyen-Van-TamJS, CarsonG, DunningJ, HarrisonEM, BaillieJK, SemdeM, CulinanP, Openshaw PJK (ISARIC investigators): Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021:S2213–2600(21)00013-8.